Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
复制标题
DOI：
10.1016/j.bmcl.2007.05.096
复制
发表时间：
2007-08
影响因子：
2.7
通讯作者：
J. Pfefferkorn;Yun-Song Song-Yun-Song-Song-51262751;Kuai-lin Sun;S. Miller;B. K. Trivedi;Chulho Choi;R. Sorenson;L. Bratton;P. Unangst;S. Larsen;T. Poel;Xue-min Cheng;Chitase Lee;Noe O. Erasga;B. Auerbach;Valerie Askew;L. Dillon;J. Hanselman;Zhiwu Lin;G. Lu;A. Robertson;Karl Olsen;T. Mertz;C. Sekerke;A. Pavlovsky;M. Harris;G. Bainbridge;N. Caspers;Huifen Chen;M. Eberstadt
中科院分区：
文献类型：
--
作者：
J. Pfefferkorn;Yun-Song Song-Yun-Song-Song-51262751;Kuai-lin Sun;S. Miller;B. K. Trivedi;Chulho Choi;R. Sorenson;L. Bratton;P. Unangst;S. Larsen;T. Poel;Xue-min Cheng;Chitase Lee;Noe O. Erasga;B. Auerbach;Valerie Askew;L. Dillon;J. Hanselman;Zhiwu Lin;G. Lu;A. Robertson;Karl Olsen;T. Mertz;C. Sekerke;A. Pavlovsky;M. Harris;G. Bainbridge;N. Caspers;Huifen Chen;M. Eberstadt
This manuscript describes the design and synthesis of a series of pyrrole-based inhibitors of HMG-CoA reductase for the treatment of hypercholesterolemia. Analogs were optimized using structure-based design and physical property considerations resulting in the identification of 44, a hepatoselective HMG-CoA reductase inhibitor with excellent acute and chronic efficacy in a pre-clinical animal models.
